• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

四方片和金匮肾气丸对糖尿病肾病患者肠道菌群及代谢的影响。

Effects of tetragonum tablets and Jin Gui Ren Qi Pill on intestinal flora and metabolism in patients with diabetic kidney disease.

作者信息

Zhang Cheng-Yu, Yue Dong-Jie, Wang Di, Wu Fei-Fei

机构信息

Department of Endocrinology and Metabolism, The Fifth People's Hospital of Chongqing, Chongqing, China.

Zhengzhou Second People's Hospital, Zhengzhou City, Henan Province, China.

出版信息

Front Pharmacol. 2024 Jul 29;15:1346168. doi: 10.3389/fphar.2024.1346168. eCollection 2024.

DOI:10.3389/fphar.2024.1346168
PMID:39139646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11319841/
Abstract

OBJECTIVE

To investigate the effects of tetragonum tablets and Jin Gui Ren Qi Pill on intestinal flora and metabolism in patients with diabetic kidney disease.

METHODS

In the study conducted at Heping Hospital of Changzhi Medical College from March 2021 to December 2022, 30 cases of patients diagnosed with diabetic nephropathy were meticulously selected as study subjects. Employing a double-blind randomized table method, these patients were randomly allocated into three groups: the control group (n = 10), the tetragonum tablets group (n = 10), and the Jin Gui Ren Qi Pill group (n = 10). The control group received standard western medical treatments for diabetic nephropathy, including serum glucose, blood lipids, blood pressure management, and other conventional therapies. In addition to the standard treatments, the tetragonum tablets group received tetragonum tablets, while the Jin Gui Ren Qi Pill group received Jin Gui Ren Qi Pill. Before and after a 4-week treatment period, various baseline parameters were assessed, including fasting blood glucose, 2-h postprandial blood glucose, triglycerides, serum total cholesterol, serum low-density lipoprotein cholesterol, serum high-density lipoprotein cholesterol, random urine microalbumin/creatinine ratio (ACR), blood creatinine (SCr), and traditional Chinese medicine evidence scores. Stool specimens were collected from all three groups before and after treatment for 16S rDNA high-throughput sequencing, followed by comprehensive analyses including OUT clustering, Alpha diversity, Beta diversity, species composition analysis, LEfSe analysis, and KEGG function prediction. Spearman correlation analysis was employed to explore the relationship between intestinal flora and clinical indicators. Furthermore, fasting peripheral venous blood was collected from patients in the Bifidobacterium tetrapunctate tablets group and the control group before and after intervention to measure the optical density values of tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), and interleukin-6 (IL-6) using the Beijing Biolite ELISA kit. This study was conducted with the approval of the Ethics Committee of Changzhi Medical College.

RESULTS

  1. The 2hPBG, total cholesterol and LDL levels were observed among patients with diabetic kidney disease (DKD) across all groups: the Jin Gui Ren Qi Pill group, the tetragonum tablets group, and the control group ( < 0.05). 2. The Jin Gui Ren Qi Pill demonstrated superior efficacy in alleviating TCM symptoms and reducing the ACR compared to both the tetragonum tablets group and the control group. Conversely, tetragonum tablets exhibited a more pronounced reduction in TC levels compared to both the Jin Gui Ren Qi Pill and control groups. Notably, tetragonum tablets effectively decreased (IL-2) levels in patients with DKD. 3. tetragonum tablets also demonstrated efficacy in reducing IL-2 levels in DKD patients. 4. Analysis of intestinal microorganism abundance and diversity before and after the intervention, as well as among the three groups, revealed no significant alterations. Similarly, comparisons of ACE, Chao, Simpson, and Shannon indices showed no statistically significant differences ( > 0.05). 5. Qualitative analysis of intestinal microorganisms before and after intervention, as well as among the three groups, indicated no significant differences. Anosim test results also did not reveal qualitative distinctions (Anosim test R = 0.021, = 0.215). 6. LEfSe analysis unveiled a noteworthy increase in Prevotella_7 abundance within the Jin Gui Ren Qi Pill group post-intervention ( < 0.05). 7. Furthermore, Chinese medicine evidence scores, body mass index, TC, and LDL levels correlated positively with the relative abundance of Tyzzerella_3 bacterial flora. Conversely, age, disease duration, and 2hPBG correlated positively with the relative abundance of Christensenellaceae_R_7 flora, while TC and LDL levels displayed a negative correlation with the relative abundance of Christensenellaceae_R_7 flora.

CONCLUSION

The combination of Jin Gui Ren Qi Pill with western medical treatment exhibited superior efficacy in ameliorating clinical symptoms and reducing the ACR in patients with DKD compared to western medical treatment alone. Furthermore, this combination therapy led to an increase in the abundance of Prevotella_7 within the intestinal flora of patients, suggesting a potential enhancement in carbohydrate metabolism by the intestinal microbiota. On the other hand, tetragonum tablets bacterial tablets combined with western medical treatment demonstrated enhanced efficacy in reducing TC levels in DKD patients compared to western medical treatment alone. Additionally, this combination therapy effectively reduced the levels of IL-2 in DKD patients, thus mitigating inflammation in these individuals.

摘要

目的

探讨复方四君子片和金匮肾气丸对糖尿病肾病患者肠道菌群及代谢的影响。

方法

在长治医学院和平医院于2021年3月至2022年12月开展的研究中,精心选取30例确诊为糖尿病肾病的患者作为研究对象。采用双盲随机表法,将这些患者随机分为三组:对照组(n = 10)、复方四君子片组(n = 10)和金匮肾气丸组(n = 10)。对照组接受糖尿病肾病的标准西医治疗,包括血糖、血脂、血压管理及其他常规疗法。除标准治疗外,复方四君子片组服用复方四君子片,金匮肾气丸组服用金匮肾气丸。在4周治疗期前后,评估各项基线参数,包括空腹血糖、餐后2小时血糖、甘油三酯、血清总胆固醇、血清低密度脂蛋白胆固醇、血清高密度脂蛋白胆固醇、随机尿微量白蛋白/肌酐比值(ACR)、血肌酐(SCr)以及中医证候评分。收集三组治疗前后的粪便标本进行16S rDNA高通量测序,随后进行包括OUT聚类、Alpha多样性、Beta多样性、物种组成分析、LEfSe分析和KEGG功能预测的综合分析。采用Spearman相关性分析探讨肠道菌群与临床指标之间的关系。此外,在双歧杆菌四联片组和对照组干预前后采集空腹外周静脉血,使用北京博奥联免疫吸附测定试剂盒测量肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)和白细胞介素-6(IL-6)的光密度值。本研究经长治医学院伦理委员会批准。

结果

  1. 在所有组的糖尿病肾病(DKD)患者中观察到餐后2小时血糖、总胆固醇和低密度脂蛋白水平:金匮肾气丸组、复方四君子片组和对照组(<0.05)。2. 与复方四君子片组和对照组相比,金匮肾气丸在缓解中医症状和降低ACR方面显示出更好的疗效。相反,与金匮肾气丸组和对照组相比,复方四君子片在降低总胆固醇水平方面表现更为显著。值得注意的是,复方四君子片有效降低了DKD患者的(IL-2)水平。3. 复方四君子片在降低DKD患者IL-2水平方面也显示出疗效。4. 干预前后及三组之间肠道微生物丰度和多样性分析显示无显著变化。同样,ACE、Chao、Simpson和Shannon指数的比较也未显示出统计学显著差异(>0.05)。5. 干预前后及三组之间肠道微生物的定性分析表明无显著差异。Anosim检验结果也未揭示定性差异(Anosim检验R = 0.021,= 0.215)。6. LEfSe分析显示,干预后金匮肾气丸组中普雷沃氏菌_7丰度显著增加(<0.05)。7. 此外,中医证候评分、体重指数、总胆固醇和低密度脂蛋白水平与泰泽氏菌_3菌群的相对丰度呈正相关。相反,年龄、病程和餐后2小时血糖与科里森氏菌_R_7菌群的相对丰度呈正相关,而总胆固醇和低密度脂蛋白水平与科里森氏菌_R_7菌群的相对丰度呈负相关。

结论

与单纯西医治疗相比,金匮肾气丸联合西医治疗在改善DKD患者临床症状和降低ACR方面显示出更好的疗效。此外,这种联合治疗导致患者肠道菌群中普雷沃氏菌_7丰度增加,提示肠道微生物群对碳水化合物代谢的潜在增强作用。另一方面,复方四君子片联合西医治疗与单纯西医治疗相比,在降低DKD患者总胆固醇水平方面显示出增强的疗效。此外,这种联合治疗有效降低了DKD患者的IL-2水平,从而减轻了这些个体的炎症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/4b7de6a9a082/fphar-15-1346168-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/24e0a4cba868/fphar-15-1346168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/a82133b64c8f/fphar-15-1346168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/a1d3a3e082ed/fphar-15-1346168-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/56d26275272c/fphar-15-1346168-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/7860c6948812/fphar-15-1346168-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/ea2cedebff2a/fphar-15-1346168-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/085cac6a5127/fphar-15-1346168-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/7959440b273f/fphar-15-1346168-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/1f8234df5c5f/fphar-15-1346168-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/85d02d1a1179/fphar-15-1346168-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/95de8805087a/fphar-15-1346168-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/e548fafa604a/fphar-15-1346168-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/e3eb49301e93/fphar-15-1346168-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/772a1385c962/fphar-15-1346168-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/4b7de6a9a082/fphar-15-1346168-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/24e0a4cba868/fphar-15-1346168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/a82133b64c8f/fphar-15-1346168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/a1d3a3e082ed/fphar-15-1346168-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/56d26275272c/fphar-15-1346168-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/7860c6948812/fphar-15-1346168-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/ea2cedebff2a/fphar-15-1346168-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/085cac6a5127/fphar-15-1346168-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/7959440b273f/fphar-15-1346168-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/1f8234df5c5f/fphar-15-1346168-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/85d02d1a1179/fphar-15-1346168-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/95de8805087a/fphar-15-1346168-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/e548fafa604a/fphar-15-1346168-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/e3eb49301e93/fphar-15-1346168-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/772a1385c962/fphar-15-1346168-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f1/11319841/4b7de6a9a082/fphar-15-1346168-g015.jpg

相似文献

1
Effects of tetragonum tablets and Jin Gui Ren Qi Pill on intestinal flora and metabolism in patients with diabetic kidney disease.四方片和金匮肾气丸对糖尿病肾病患者肠道菌群及代谢的影响。
Front Pharmacol. 2024 Jul 29;15:1346168. doi: 10.3389/fphar.2024.1346168. eCollection 2024.
2
Corrigendum: Effects of tetragonum tablets and Jin Gui Ren Qi Pill on intestinal flora and metabolism in patients with diabetic kidney disease.勘误:四方片和金匮肾气丸对糖尿病肾病患者肠道菌群及代谢的影响。
Front Pharmacol. 2024 Sep 12;15:1480859. doi: 10.3389/fphar.2024.1480859. eCollection 2024.
3
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.用于糖尿病肾病治疗与管理的中药的临床疗效、潜在机制及分子靶点。
Acta Pharm Sin B. 2021 Sep;11(9):2749-2767. doi: 10.1016/j.apsb.2020.12.020. Epub 2021 Feb 2.
4
Effects of Jian Pi Qu Shi Formula on intestinal bacterial flora in patients with idiopathic membranous nephropathy: A prospective randomized controlled trial.健脾祛湿方对特发性膜性肾病患者肠道菌群的影响:一项前瞻性随机对照试验。
Chronic Dis Transl Med. 2020 May 30;6(2):124-133. doi: 10.1016/j.cdtm.2020.04.004. eCollection 2020 Jun.
5
[A preliminary study on the effects of fecal microbiota transplantation on the intestinal microecology of patients with severe pneumonia during the convalescence period].粪菌移植对重症肺炎恢复期患者肠道微生态影响的初步研究
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Apr;35(4):352-357. doi: 10.3760/cma.j.cn121430-20221206-01065.
6
[Effect of moxibustion at "Mingmen" (GV 4) and "Guanyuan" (CV 4) on immune function in healthy rats based on intestinal flora].基于肠道菌群探讨艾灸“命门”(GV 4)与“关元”(CV 4)对健康大鼠免疫功能的影响
Zhongguo Zhen Jiu. 2023 Oct 12;43(10):1157-64. doi: 10.13703/j.0255-2930.20220819-k0001.
7
Efficacy of Yishen Huashi Granules Combined with Linagliptin Tablets on Blood Glucose and Renal Function in Patients with Type 2 Diabetic Nephropathy.益肾化湿颗粒联合利拉鲁肽片治疗 2 型糖尿病肾病患者的疗效及对血糖、肾功能的影响。
Comput Intell Neurosci. 2022 Sep 20;2022:4272520. doi: 10.1155/2022/4272520. eCollection 2022.
8
Correlations of changes in inflammatory factors, glucose and lipid metabolism indicators and adiponectin with alterations in intestinal flora in rats with coronary heart disease.冠心病大鼠炎症因子、糖脂代谢指标及脂联素变化与肠道菌群改变的相关性。
Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10118-10125. doi: 10.26355/eurrev_202010_23231.
9
[Relationship between Blood Glucose and Lipid Levels and Intestinal in Middle-Aged and Older Adults in Chengdu].[成都中老年人群血糖、血脂水平与肠道的关系]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Mar;53(2):297-302. doi: 10.12182/20220360105.
10
[Protective effect and mechanism of Bifidobacterium bifidum TMC3115 on long-term colitis in mice which exposed to antibiotic in early life].双歧双歧杆菌TMC3115对生命早期暴露于抗生素的小鼠长期结肠炎的保护作用及机制
Wei Sheng Yan Jiu. 2022 Jul;51(4):624-644. doi: 10.19813/j.cnki.weishengyanjiu.2022.04.021.

引用本文的文献

1
Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions.糖尿病肾病:从发病机制到多模式治疗——当前证据与未来方向
Front Med (Lausanne). 2025 Aug 8;12:1631053. doi: 10.3389/fmed.2025.1631053. eCollection 2025.
2
The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy.IgA肾病和膜性肾病中肠道微生物群的失调及代谢物的调节异常。
Front Med (Lausanne). 2025 Jul 16;12:1618947. doi: 10.3389/fmed.2025.1618947. eCollection 2025.
3
Fecal microbiota transplantation is a promising therapy for kidney diseases.

本文引用的文献

1
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.国际糖尿病联盟(IDF)糖尿病地图集:2021 年全球、区域和国家糖尿病患病率估算值以及 2045 年预测值。
Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6.
2
The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.肠道微生物组在糖尿病和肥胖相关肾脏疾病中的作用。
Int J Mol Sci. 2021 Sep 6;22(17):9641. doi: 10.3390/ijms22179641.
3
Bifidobacterium dentium N8 with potential probiotic characteristics prevents LPS-induced intestinal barrier injury by alleviating the inflammatory response and regulating the tight junction in Caco-2 cell monolayers.
粪便微生物群移植是一种很有前景的肾脏疾病治疗方法。
Front Med (Lausanne). 2025 Jul 9;12:1628722. doi: 10.3389/fmed.2025.1628722. eCollection 2025.
4
Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation.靶向糖尿病肾病中的离子通道网络:从分子串扰到精准治疗与临床创新
Front Med (Lausanne). 2025 Jun 26;12:1607701. doi: 10.3389/fmed.2025.1607701. eCollection 2025.
5
A bibliometric study of global trends in diabetic nephropathy and intestinal flora research.糖尿病肾病与肠道菌群研究全球趋势的文献计量学分析
Front Microbiol. 2025 May 21;16:1577703. doi: 10.3389/fmicb.2025.1577703. eCollection 2025.
6
Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis.肠道微生物群调节氧化应激和炎症:肾纤维化中的双刃剑。
Cell Mol Life Sci. 2024 Dec 5;81(1):480. doi: 10.1007/s00018-024-05532-5.
具有潜在益生菌特性的齿双歧杆菌 N8 通过减轻炎症反应和调节 Caco-2 细胞单层中的紧密连接来预防 LPS 诱导的肠道屏障损伤。
Food Funct. 2021 Aug 21;12(16):7171-7184. doi: 10.1039/d1fo01164b. Epub 2021 Jul 16.
4
Prevotella diversity, niches and interactions with the human host.普雷沃氏菌多样性、生态位及其与人类宿主的相互作用。
Nat Rev Microbiol. 2021 Sep;19(9):585-599. doi: 10.1038/s41579-021-00559-y. Epub 2021 May 28.
5
Gut species in health and disease.肠道物种在健康和疾病中的作用。
Gut Microbes. 2021 Jan-Dec;13(1):1-20. doi: 10.1080/19490976.2020.1848158.
6
Indole-3-lactic acid associated with Bifidobacterium-dominated microbiota significantly decreases inflammation in intestinal epithelial cells.吲哚-3-乳酸与双歧杆菌主导的微生物群显著降低肠道上皮细胞的炎症。
BMC Microbiol. 2020 Nov 23;20(1):357. doi: 10.1186/s12866-020-02023-y.
7
Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment".特刊“糖尿病肾病:诊断、预防与治疗”。
J Clin Med. 2020 Mar 17;9(3):813. doi: 10.3390/jcm9030813.
8
The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health.人类肠道细菌 Christensenellaceae 分布广泛、可遗传,并与健康有关。
BMC Biol. 2019 Oct 28;17(1):83. doi: 10.1186/s12915-019-0699-4.
9
Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease.革兰氏阴性肠道微生物群失调及相关血清脂多糖会加重2型糖尿病合并慢性肾脏病患者的炎症反应。
Exp Ther Med. 2019 Nov;18(5):3461-3469. doi: 10.3892/etm.2019.7943. Epub 2019 Aug 26.
10
Diabetic nephropathy: An update on pathogenesis and drug development.糖尿病肾病:发病机制与药物研发的最新进展
Diabetes Metab Syndr. 2019 Jan-Feb;13(1):754-762. doi: 10.1016/j.dsx.2018.11.054. Epub 2018 Nov 30.